Revenue Breakdown
Composition ()
No data
Revenue Streams
Johnson & Johnson (JNJ) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Oncology-DARZALEX, accounting for 14.9% of total sales, equivalent to $3.54B. Other significant revenue streams include Immunology-STELARA and Cardiovascular-ELECTROPHYSIOLOGY. Understanding this composition is critical for investors evaluating how JNJ navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Johnson & Johnson maintains a gross margin of 67.79%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 23.75%, while the net margin is 20.83%. These profitability ratios, combined with a Return on Equity (ROE) of 35.03%, provide a clear picture of how effectively JNJ converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, JNJ competes directly with industry leaders such as ABBV and ONC. With a market capitalization of $598.69B, it holds a leading position in the sector. When comparing efficiency, JNJ's gross margin of 67.79% stands against ABBV's 72.61% and ONC's 86.09%. Such benchmarking helps identify whether Johnson & Johnson is trading at a premium or discount relative to its financial performance.
